LIALDA NEWS HIGHLIGHTS Media Articles Related to Lialda (Mesalamine)
Mesalamine Granules Maintain Remission In Ulcerative Colitis Patients Who Switch From Another 5-ASA
Source: Irritable-Bowel Syndrome News From Medical News Today [2008.10.08]
APRISO(TM) Granted FDA Marketing Approval For Maintenance Of Remission Of Ulcerative Colitis
Source: Irritable-Bowel Syndrome News From Medical News Today [2008.11.04]
APRISO™ Granted FDA Marketing Approval For Maintenance Of Remission Of Ulcerative Colitis
Source: Irritable-Bowel Syndrome News From Medical News Today [2008.11.03]
Published Studies Related to Lialda (Mesalamine)
Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. [2008.10]
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. [2007.12]
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. [2007.01]
Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. [2007.01]
Double-blind pilot study of mesalamine vs. placebo for treatment of chronic diarrhea and nonspecific colitis in immunocompetent HIV patients. [2006.01]
Clinical Trials Related to Lialda (Mesalamine)
A Study Comparing the Acceptability of Pentasa® Sachets Versus Pentasa® Tablets in Children With Crohn´s Disease [Completed]
Once Daily Versus Conventional Dosing of Asacol in the Maintenance of Quiescent Ulcerative Colitis [Terminated]
The Influence of 5–Aminosalicylates on Thiopurine Metabolite Levels [Completed]
The CODA Study (Colitis Once Daily Asacol) [Recruiting]
Canadian Active & Maintenance Modified Pentasa Study [Recruiting]
|
